Therapy for chemotherapy-induced peripheral neuropathy - In reply

JAMA

Volumn 310, Issue 5, 2013, Pages 538-

  Lavoie Smith, Ellen M ^a   Pang, Herbert ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF NURSING   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DULOXETINE; OXALIPLATIN; PLACEBO; TAXANE DERIVATIVE;

CHRONIC PAIN; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LETTER; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84881244602     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.7905     Document Type: Letter

References (4)

1. Clauw DJ. Pain management: fibromyalgia drugs are 'as good as it gets' in chronic pain. Nat Rev Rheumatol. 2010;6(8):439-440.
2. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998;78(3):209-216. (Pubitemid 29052278)
3. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149(2):177-193.
4. Bingel U, Wanigasekera V, Wiech K, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3(70):70ra14.